Method and system for spectral data analysis

Abstract

To determine the characteristics of proteins, peptides, and / or peptoids via two-dimensional correlation spectroscopy and / or two-dimensional co-distribution spectroscopy.SOLUTION: Spectral data of proteins, peptides, and / or peptoids can be obtained with respect to an applied perturbation. Two-dimensional co-distribution analysis can be applied to generate an asynchronous co-distribution plot for the proteins, peptides, and / or peptoids to define the population of proteins in a solution. In the two-dimensional asynchronous plot, a cross peak can be identified as correlating with an auto peak in the two-dimensional correlation synchronous plot associated with aggregation of the proteins, peptides, and / or peptoids. The two-dimensional asynchronous cross peak can be used to determine the order of the presence of distributed spectral intensities with respect to the applied perturbation.SELECTED DRAWING: Figure 1A

Description

[Technical field]

[0001] The present invention relates to a method and system for spectral data analysis. Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 62 / 281,630, filed Jan. 21, 2016, which is incorporated by reference in its entirety. [Background technology]

[0002] The phenomenon of protein aggregation is widespread throughout industrial bioprocessing. Proteins are expensive to express, isolate and purify due to their complex physicochemical properties. Aggregation is considered the primary mode of protein degradation, sometimes leading to immunogenicity, anti-drug antibody responses (ADA) in patients and loss of efficacy. Detecting and characterizing protein aggregates is a major objective in the biopharmaceutical industry and other areas of scientific research. Summary of the Invention [Problem to be solved by the invention]

[0003] The formation of protein aggregates is important in industrial applications as it can significantly affect the production of protein therapeutics (ie, biologics or biosimilars), effectively reducing production yields. [Means for solving the problem]

[0004] The subject technology is described, for example, according to various aspects described below. Various examples of aspects of the subject technology are described below. These are provided as examples and not as limitations of the subject technology.

[0005] Aspects of the subject technology provide methods for determining aggregation in protein, peptide and / or peptoid formulations in solution or in a lyophilized state without the use of probes or additives.

[0006] In accordance with aspects of the subject technology, protein samples are spectroscopically analyzed and the spectral data is analyzed using established methods to determine the feasibility of the protein samples, and / or portions thereof, can be fully automated and used to determine the mechanism of aggregation.

[0007] In accordance with aspects of the subject technology, the methods described herein can be applied to membrane proteins, hydrophilic proteins, peptides and peptoids, either as single components or as binary or ternary mixtures with other peptides or lipid mixtures, in which case one of the components must be isotopically labeled to allow for simultaneous detection of each component.

[0008] Aspects of the subject technology allow for flexibility in sample preparation, the potential for automating it, and data analysis that demonstrates the utility of sample preparation for pharmaceutical protein formulations. In accordance with aspects of the subject technology, the methods described herein can be applied to any protein, peptide or peptoid sample in several environments, such as aqueous or lipid. The methods described herein can be used qualitatively and / or quantitatively to determine protein aggregation. Data analysis is performed in which the mechanism of protein aggregation can be determined and the stability and / or viability of the protein, peptide or peptoid can be determined.

[0009] In accordance with one aspect of the subject technology, methods involve transmission Fourier transform infrared ("FT-IR") spectroscopy and / or attenuated total reflectance ("ATR") spectroscopy, quantum cascade laser microscopy ("QCL"), two-dimensional correlation spectroscopy ("2DCOS"), and / or two-dimensional codistribution spectroscopy ("2DCDS") to analyze these proteins, peptides, or peptoids. In accordance with aspects of the subject technology, the spectral data may be obtained using any suitable method and instrumentation, such as an FT-IR spectrometer, an FT-IR microscope, a QCL spectrometer, or a QCL microscope. In aspects of the subject technology, it is preferred to obtain the spectral data using a QCL microscope.

[0010] Methods, systems, and instructions for processing data representative of protein, peptide, and / or peptoid characteristics may include obtaining spectral data for the protein, peptide, and / or peptoid with respect to an applied perturbation, applying two-dimensional codistribution analysis to generate an asynchronous codistribution plot of the protein, peptide, and / or peptoid, identifying cross-peaks in the asynchronous codistribution plot that correlate with autopeaks associated with aggregation of the protein, peptide, and / or peptoid, and using the cross-peaks to determine an order of occurrence of distributed spectral intensities with respect to the applied perturbation.

[0011] Using the cross peaks may include determining whether, for two wave numbers v1 and v2, the cross peaks corresponding to the two wave numbers have a positive value, and determining that when the cross peaks have a positive value, the spectral intensity present at v1 is distributed within an interval of the applied perturbation that is lower than the interval in which the spectral intensity present at v2 is distributed. Using the cross peaks may include determining whether, for two wave numbers v1 and v2, the cross peaks corresponding to the two wave numbers have a negative value, and determining that when the cross peaks have a negative value, the spectral intensity present at v2 is distributed within an interval of the applied perturbation that is lower than the interval in which the spectral intensity present at v1 is distributed.

[0012] The operations may include applying two-dimensional correlation analysis to generate a synchronization plot for the protein, peptide and / or peptoid, identifying a synchronization peak in the synchronization plot that is associated with aggregation of the protein, peptide and / or peptoid, and using the synchronization peak to determine the degree of overlap of the distribution patterns of spectral intensity with respect to an applied perturbation.

[0013] The operations may also include applying two-dimensional correlation analysis to generate synchronous and asynchronous plots for the proteins, peptides and / or peptoids, identifying positive cross-peaks in the synchronous plots that correlate with autopeaks associated with protein, peptide and / or peptoid aggregation, and using the identified peak intensities of the spectral data to determine the amount of protein, peptide and / or peptoid aggregation.

[0014] The amount of protein, peptide and / or peptoid aggregation may be compared to the order of occurrence of the distributed spectral intensity with respect to the applied perturbation. Regions of interest may be recognized for identification of particulates and solutions. The size and number of particulates may be determined to confirm the population distribution of particulates. The spectral data may be analyzed to verify the signal to noise ratio, perform baseline correction, determine water vapor content, and / or determine signal intensity within a spectral region. Covariance or dynamic spectral data may be generated based on the perturbation of the sample. Changes including peak intensities may be correlated in the spectral data that are in phase with each other, such as obtained in a synchronous plot. Elements that change in the spectral data may be determined. The overall maximum intensity change in the spectral data may be determined. The overall minimum intensity change in the spectral data may be determined. The minimum number of underlying spectral contributions in a band, performing curve fitting analysis, and secondary structure composition of the sample may be determined. Changes including peak intensities may be correlated in the spectral data that are out of phase with each other, such as obtained in an asynchronous plot.

[0015] Additional features and advantages of the subject technology will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by the practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and claims hereof, as well as the appended drawings.

[0016] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the claimed subject matter.

[0017] The accompanying drawings, which are included to provide a further understanding of the subject technology, and which are incorporated in and constitute a part of this description, illustrate aspects of the subject technology and, together with the description, serve to explain the principles of the subject technology. [Brief description of the drawings]

[0018] [Figure 1A] 1A, 1B, and 1C show the results of orthogonal bioanalytical techniques used to determine protein aggregation, according to some aspects of the subject technology: Figure 1A is a graph showing the results of size exclusion chromatography ("SEC"). [Figure 1B] FIG. 1B is a graph showing the results of differential scanning calorimetry ("DSC"). [Figure 1C] FIG. 1C is a graph showing the results of dynamic light scattering ("DLS"). [Diagram 2] 1 is a flowchart illustrating different aspects of a method in accordance with some aspects of the subject technology. [Diagram 3] FIG. 1 is a block diagram showing the results of multi-stage analysis. [Figure 4] 1 is a diagram of an example computing system in accordance with some aspects of the subject technology. [Diagram 5] 1 is a flowchart illustrating the operations of an example method in accordance with some aspects of the subject technology. [Figure 6] 1 is a flowchart illustrating the operations of an example method in accordance with some aspects of the subject technology. [Figure 7-1] The results of the multi-level analysis are shown below. [Figure 7-2] The results of the multi-level analysis are shown below. [Figure 8]FIG. 8A shows a comparison of the amino acid sequences of candidate ADC fragments for developability assessment. ADC fragment 0 ("ADC0"; SEQ ID NO:1) is a full-length fragment containing seven additional amino acids (APELLGG; SEQ ID NO:2) at the N-terminus. ADC fragment 1 ("ADC1"; SEQ ID NO:3) is truncated at the N-terminus as if the top fragment contained one disulfide bridge. ADC fragment 2 ("ADC2"; SEQ ID NO:4) has two point mutations (L5C / K97C) compared to ADC fragment 1, thus adding an additional disulfide bridge to stabilize ADC fragment 2. FIG. 8B shows a Richardson ribbon model, which consists mainly of β-sheets, β-turns and hinges, and two short helices within the ADC fragments. There are three Arg residues at the N-terminus, C-terminus, positions 25, 62 and 71, adjacent Pro residues at positions 27 and 61, and disulfide bonds Cys31 and Cys91. These three arginine residues serve as internal probes for the ADC. [Figure 9] Figures 9A and 9B show and identify the size of the aggregates. Figure 9A shows the QCL infrared spectral overlay for ADC0 and ADC1. Figure 9B shows the plots at 24°C and 28°C, respectively. All ADC fragments were fully H→D exchanged. Furthermore, the amide I' band maximum at 24°C corresponds to aggregated ADC1, and the maximum at 28°C corresponds to ADC1 in DO solution. [Figure 10] The results of a co-distribution analysis are shown. The aggregation mechanism involves arginine residues within the protein and selected antiparallel β-sheets and β-turns. As a result, this analysis provides the regions of the protein that are undergoing aggregation. [Figure 11] Figure 11A shows a QCL microscopy image and Figure 11B shows the relevant QCL spectrum of ADC Fragment 2 in 15% sucrose, which can be used to confirm the presence and amount of both excipients and protein candidates. [Figure 12]Figures 12A, 12B and 12C show QCL spectral results acquired for ADC2 in the spectral region 1400-1800 cm-1 at 26 °C in HEPES pH 6.6 in the presence of NaCl and different amounts of sucrose as excipients (Figure 12A: 15% sucrose, Figure 12B: 30% sucrose, and Figure 12C: 60% sucrose). These results demonstrate the extent to which quantitative analysis can be performed and provide crucial information that would otherwise be difficult to obtain. Protein stability and conformation can be ascertained under desired excipient conditions while also allowing for the determination of the concentration of the protein of interest and its excipients in solution. Furthermore, no aggregate species were observed for ADC2 under these conditions. [Figure 13] Table showing the results of a normal distribution analysis performed on 43 experiments using QCL microscopy under different conditions. The QbD experimental setup analyzed 324 spectral data representing the evaluation of ADC Fragment 2 in the presence of different amounts of NaCl, sucrose, and different ratios of both excipients (i.e., NaCl and sucrose). [Figure 14] 1 shows the results of the DOE stepwise model fitting, including predicted profiles for the QCL microscopy spectral data of ADC2 using the second best fitting model (AIC model). [Figure 15] DOE stepwise model fitting results are shown, including predicted profiles for QCL microscopy spectral data of ADC2 using the best fit model (BIC model). Results suggest 18.5% sucrose as the best excipient for ADC2 at near room temperature conditions. [Figure 16] Figures 16A and 16B show 2D IR correlation plots (Figure 16A: synchronous, Figure 16B: asynchronous) for ADC fragment 2 in the presence of HEPES and 15% sucrose within the temperature range of 26-28 °C. The amide I' and side chain bands were investigated in the spectral region 1720-1500 cm-1. In the synchronous plot (Figure 16A), ADC2 was observed to have predominantly β-sheet and β-turn secondary structure with no aggregate species present. [Figure 17]The sequence of events for ADC Fragment 2 in 50 mM HEPES, 150 mM NaCl, 3 mM KCl and 15% sucrose at pH 6.6 and 26° C., used to confirm the role of sucrose in stabilizing proteins, is shown. [Figure 18] Figures 18A and 18B show 2D IR codistribution plots (Figure 18A: synchronous, Figure 18B: asynchronous) of ADC2 with HEPES and 15% sucrose as excipients at temperatures ranging from 26 to 28 °C. Side chains with π-helices and β-turns (hinge loops) were perturbed at low temperature. [Figure 19] A representative curve fit analysis for ADC fragment 2 in D2O using band assignments generated from 2D IR correlation analysis is shown, and 80.4 + / - 1.1% of the protein was determined to contain β structure (see also Tables 2 and 3). [Figure 20] Figure 20A shows overlaid spectra showing the amide I, II and III bands for NIST mAb (50 mg / mL) in the MID IR spectral region 1750-1400 cm-1 acquired in HO within the temperature range of 24-60° C. Figures 20B and 20C show 2D IR correlation plots (Figure 20B: synchronous, Figure 20C: asynchronous) for the sample of Figure 16A. [Figure 21] Figure 21A shows overlaid spectra showing both the amide I and II bands for NIST mAb (50 mg / mL) in the MID IR spectral region 1750-1500 cm-1 acquired in HO within the temperature range of 24-60° C. Figures 21B and 21C show 2D IR correlation plots (Figure 21B: synchronous, Figure 21C: asynchronous) for the sample in Figure 21A. [Figure 22] The sequence of events for NIST mAb (50 mg / mL) in HO under thermal stress within the temperature range of 24 to 60 °C is shown. [Diagram 23] FIG. 23 shows asynchronous 2D IR co-distribution analysis plots for NIST mAb (50 mg / mL) in HO under thermal stress within the temperature range of 24-60 °C. [Figure 24-1]Figures 24A and 24B show reproductions of the plots of Figures 21A and 21B, respectively, with the addition of vertical dashed lines that intersect the autopeaks of the synchronous plot 2D IR correlation analysis plot (Figure 24B). [Figure 24-2] Figures 24C and 24D show reproductions of the plots of Figures 21C and 22, respectively, with the addition of vertical dashed lines that intersect the autopeaks of the synchronous plot 2D IR correlation analysis plot (Figure 24B). [Diagram 25] Figure 25A shows overlaid spectra showing both amide I and II bands for BSA (40 mg / mL) in the MID IR spectral region 1750-1500 cm-1 acquired in HO within the temperature range of 24-60° C. Figures 25B and 25C show 2D IR correlation plots (Figure 25B: synchronous, Figure 25C: asynchronous) for the sample in Figure 25A. [Figure 26] FIG. 26 shows the sequence of events for BSA (40 mg / mL) in HO under thermal stress (24-60° C.). [Figure 27] Asynchronous 2D IR codistribution analysis plot for BSA (40 mg / mL) in H2O under thermal stress within the temperature range of 24–60 °C and the spectral region of 1750–1380 cm-1. [Figure 28-1] FIG. 28A shows overlaid spectra showing both amide I and II bands for a NIST mAb / BSA (1:2 molar ratio) mixture in the spectral region 1750-1500 cm-1 acquired in HO within the temperature range of 24-60 °C. [Figure 28-2] 28B and 28C show 2D IR correlation analysis plots (FIG. 28B: synchronous, FIG. 28C: asynchronous) for the sample in FIG. 28A. [Figure 29] Figure 29A shows overlaid spectra showing both amide I and II bands for lysozyme (600 mg / mL) in the spectral region 1750-1500 cm acquired in HO within the temperature range of 24-60° C. Figures 29B and 29C show 2D IR correlation plots (Figure 29B: synchronous, Figure 29C: asynchronous) for the sample in Figure 29A. [Diagram 30] FIG. 30 shows the sequence of events for lysozyme (600 mg / mL) in HO under thermal stress (24-60° C.). [Diagram 31] Asynchronous 2D IR codistribution analysis plot for lysozyme (600 mg / mL) in H2O under thermal stress within the temperature range of 24–60 °C and the spectral region of 1750–1500 cm-1. [Diagram 32] 1 is an exemplary diagram of a computing system. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The following detailed description will describe specific details to facilitate understanding of the subject technology. However, it will be apparent to those skilled in the art that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and methods are not shown in detail so as not to obscure the subject technology.

[0020] Proteins are large organic compounds made up of amino acids arranged in linear chains and joined together by peptide bonds between the carboxyl and amino groups of adjacent amino acid residues. Most proteins fold into unique three-dimensional structures. The shape into which a protein naturally folds is known as the native state. While many proteins can fold unaided simply due to the chemical properties of their amino acids, some require the assistance of molecular chaperones to fold into the native state. There are four distinct modes of protein structure: · Primary structure: amino acid sequence. Secondary structure: regularly repeating local structures stabilized by hydrogen bonds. Because secondary structure is local, many regions of different secondary structure can exist within the same protein molecule. · Tertiary structure: The overall shape of a single protein molecule and the spatial relationship of the secondary structures to each other. · Quaternary structure: The shape or structure resulting from the interaction of two or more protein molecules, in this context usually called protein subunits, which function as part of a larger assembly or protein complex.

[0021] Proteins are not completely rigid molecules. In addition to these structural levels, proteins may change between several related structures while performing their biological functions. In relation to these functional rearrangements, these tertiary or quaternary structures are usually referred to as "conformations" and the transitions between them are called conformational changes.

[0022] Protein aggregation is characterized as the grouping of rigid misfolded proteins and is considered a widespread phenomenon throughout industrial bioprocessing. Aggregation is considered the primary mode of protein degradation and often leads to protein immunogenicity, leading to loss of biological activity. Protein aggregation is of crucial importance in a wide range of biomedical contexts, ranging from pathological pathologies such as Alzheimer's and Parkinson's diseases, to protein drug production, stability and delivery. Protein aggregation, which may be amorphous or fibrillar in nature, can be initiated by one of two different mechanisms: A) autoaggregation, where a partially folded intermediate is the direct precursor of aggregation, and B) heteroaggregation, where the aggregation of one protein is mediated by another protein.

[0023] The formation of protein aggregates is critical in industrial applications, as it can significantly affect the production of protein-based drugs or commercial enzymes, significantly reducing production yields. The biologics and biosimilars industry is involved in the research, development, and manufacture of complex drugs, including protein therapeutics. Research and development efficiency can be undesirably low, which increases the cost of drug development due to high attrition rates of protein therapeutics. The cost of protein therapeutic development is significantly affected by late-stage failures. One means of lowering research and development costs is to perform a series of evaluations of protein therapeutic candidates early in the research and development phase. By performing characterization of therapeutic proteins under different formulation conditions and stressors early in the research and development phase, a predictive profile of the therapeutic candidate is generated to assess the risk of protein aggregation. This approach is defined as a developability assessment. This assessment can provide important information for decision-making, such as selecting protein therapeutic candidates for further development. When protein aggregation occurs, protein therapeutics typically have reduced efficacy and can generate immune responses. In severe cases, such immune responses can be fatal.

[0024] Several methods have been proposed in the past for the determination of aggregates in mixtures. These conventional methods are designed either for a specific protein or peptide and / or require the addition of exogenous probes, and therefore do not represent a generalized method that applies generally to a class of biomolecules. Several spectroscopic techniques have been used, such as UV-Vis spectroscopy utilizing probes, and fluorescence spectroscopy, which also uses internal or exogenous probes. Similarly, near-ultraviolet circular dichroism ("CD") has also been used, but is limited to detection in the immediate vicinity of aggregates, and nuclear magnetic resonance ("NMR") can be used to detect protein aggregation by the appearance of band broadening. Sedimentation analysis can also be used to determine the degree of oligomerization, as long as the protein of interest has a sufficiently large molar extinction coefficient. Chromatographic techniques such as size exclusion can also detect the presence of protein aggregates. However, these techniques may require the use of exogenous probes, i.e., large amounts of protein, are time consuming, and do not allow for determination of the aggregation mechanism.

[0025] The problem of protein aggregation is complex and often involves several different chemical and / or computational processes that are difficult to distinguish. Aggregation may be stress-induced and involve physical or chemical changes such as agitation, oxidation, deamination and temperature changes. Even slight changes in pH, salt conditions, protein concentration or formulation conditions can also induce protein aggregation. Aggregation also leads to lower production yields, loss of efficacy of protein therapeutics, and safety concerns regarding immunogenicity risks. Currently available techniques to assess aggregation do not address all of the factors involved in the process, such as the size, identity, mechanism and extent of aggregation, and the stability of protein therapeutics in solution. Several techniques have been developed to address the size of aggregates or particulates, but do not determine the identity. Some techniques can determine the size and identity of aggregates, but cannot determine the extent of aggregation. The amino acid side chains present in proteins are an important contributor to protein stability. However, the relationship between the weak chemical interactions observed in the side chains and the stability of the secondary structure of the protein cannot be determined using routine bench instrumentation in high-throughput processing.

[0026] Protein therapeutic stability is also critical for drug development and cannot be fully characterized by simply identifying the thermal transition temperature of a protein. A greater degree of understanding is needed to understand and address the stability of protein therapeutics. For example, it would be beneficial to understand 1) the relative stability of domains within a protein of interest, 2) how amino acid side chains contribute to domain stability, 3) whether amino acid side chains are involved in the aggregation mechanism, and 4) whether excipients can stabilize weak interactions (e.g., at amino acid side chains) within critical regions of specific domains of protein therapeutics. There is a gap in understanding the parameters that are important for determining the mechanism of protein aggregation.

[0027] When using currently available commercially available methods statistically independently, differences in sensitivity of the available methods are a concern. Generally, such methods focus on determining the size, purity, and stability of protein therapeutics to achieve lot-to-lot consistency, and evaluate the presence or absence of protein aggregates or particulates in the formulation.

[0028] There is a need for techniques that can be used to better assess the viability of protein therapeutics, as well as the comparability assessments necessary to maintain and ensure the integrity, efficacy and safety of the products. Such processes will need to be recognized by the Food and Drug Administration's ("FDA") Center for Drug Evaluation and Research ("CDER") Division and other relevant regulatory agencies as sufficient to ensure the integrity, efficacy and safety of the products.

[0029] A solution to the protein aggregation problem for the biopharmaceutical industry would lead to (1) reduced R&D costs, (2) increased product yields, thereby ensuring product demand and supply, (3) reduced risk of recalls, (4) increased FDA approval rates, (5) reduced time to market, and (6) increased valuations. Also, a pipeline of new protein therapeutics would be primed to address chronic diseases such as cancer, rheumatoid arthritis, Crohn's disease, and neurodegenerative disorders, among others, thereby improving the quality of life for patients.

[0030] Aspects of the subject technology provide a fast, accurate and reproducible method to determine the size, identity, mechanism and extent of aggregation and stability of protein therapeutics or other chemicals in a single experiment. Aspects of the subject technology address comparability assessment of different protein therapeutic candidates, and viability assessment of protein therapeutic candidates. The data can be used for classification and chemical characterization of proteins, polymers, organics, inorganics for discovery, research and development, at pilot scale or in production, or for quality control and assurance purposes. It can also be used for stability assessment of protein therapeutics during storage and delivery.

[0031] The computer-based method and system described herein provides a significant improvement over existing analysis for proteins.The computer-based method and system described herein generates and stores data in a form that facilitates efficient and meaningful analysis without requiring the use of multiple instruments.Therefore, the computer-based method and system described herein can improve the efficiency of spectral data analysis for evaluating candidate drugs.

[0032] Aspects of the subject technology include the use of two-dimensional correlation spectroscopy ("2DCOS") and two-dimensional codistribution spectroscopy ("2DCDS") to provide essential information on the extent and mechanism of aggregation of protein therapeutics. The methods described herein can include analysis of side chain modes as internal probes, providing information that confirms the stability of structural motifs or domains within proteins. The methods described herein have been found to be useful in High Throughput-Developability and Comparability Assessment ("HT-DCA") through a Quality by Design ("QBD") compliant Design of Experiments ("DOE") approach.

[0033] According to some embodiments, the systems and methods described herein may also be used to determine protein-protein interactions ("PPIs") or protein-polymer interactions (protein-lipid interactions, protein-DNA or protein-RNA interactions, or protein-drug interactions). The systems and methods described herein may also be used to analyze organic solutions, polymers, gels, nanostructures, or small liquid crystals, and the like.

[0034] FIG. 1A shows the results of size exclusion chromatography ("SEC"), FIG. 1B shows the results of differential scanning calorimetry ("DSC"), and FIG. 1C shows the results of dynamic light scattering ("DLS"). Although these techniques can lead to the determination of the size, identity and extent of aggregation, none of them can define the mechanism of aggregation. Understanding the mechanism of aggregation is fundamental in the development of protein drugs to ensure their potential to work as intended with little or no risk of immunogenicity.

[0035] According to some embodiments, as shown in FIG. 2, samples from different parts of the bioprocess, which may be aqueous or lyophilized, are monitored by Fourier transform infrared (ATR or transmission) spectroscopy ("FT-IR") and analyzed using 2DCOS to look for aggregates. Other types of analysis, such as Raman spectroscopy, quantum cascade laser absorption, synchrotron radiation source Fourier transform infrared microscopy and / or combinations thereof, may also be used. If aggregates are found, an evaluation procedure may be initiated, which may include comparing the results to an established database, and as a result, the protocol used in the bioprocess may be modified or changed. FT-IR spectroscopy allows a high degree of flexibility and speed in determining protein aggregates, with limited manipulation and without the use of exogenous probes. An exemplary method may include FT-IR spectroscopy in combination with 2DCOS, which allows the determination of the presence or absence of aggregates, i.e., the aggregation mechanism, and allows the modification of the protein pipeline manufacturing process to once again generate a viable protein. Another exemplary method can include quantum cascade laser microscopy in combination with 2DCOS, which allows for the determination of the presence or absence of aggregates, i.e., the aggregation mechanism, and allows for modification of the protein pipeline manufacturing process to once again generate a viable protein. In addition, the temperature transition of the protein can also be determined, and a 2DCOS plot can be generated to compare with a proven viable protein, allowing for quality control, stability, and feasibility of the desired protein product. Furthermore, facilitating sample preparation and data analysis allows for automation of the method.

[0036] FT-IR spectroscopy is sensitive to conformational changes and aggregation. This technique allows for qualitative and quantitative analysis of the extent of protein, peptide and peptoid aggregation. The use of 2DCOS allows for further analysis and provides mechanistic information about the aggregation process. Methods may incorporate one or more of the following techniques: transmission FT-IR spectroscopy, attenuated total reflectance ("ATR") FT-IR spectroscopy, 2DCOS analysis and / or 2DCDS analysis.

[0037] For transmission FT-IR or QCL microscopy, sample preparation may involve the use of pure proteins, peptides or peptoids in an appropriate buffer. Samples may be lyophilized and resuspended in D2O. Protein solution may be added between the slide and cover and sealed to prevent solvent evaporation. Slides may be placed in a slide holder. A similar procedure is used for reference, using an appropriate buffer (PBS or HEPES). A temperature probe located in close proximity to the slide is used to register the temperature of the sample. A temperature gradient with time may be used and the acquired spectral data is automatically received by a thermocouple interface. During spectral analysis, the full width at half height (FWHH) of the amide I band may be determined as a function of temperature, establishing the transition temperature.

[0038] Attenuated total reflectance (ATR) FT-IR spectroscopy can be used for hydrogen / deuterium exchange studies, titration experiments, and determining the orientation of reconstituted membrane proteins. In this method, the protein can be fully exchanged by repeated freeze-drying and redissolving the sample in D2O. The fully exchanged protein sample and buffer can be spread as thin films independently, with the buffer taken as a reference. The protein sample, typically in D2O, is spread on an ATR crystal and allowed to dry using a dry air purge. The subsequent spectrum will be representative of the protein sample and, if present, the aggregated form of the protein.

[0039] According to some embodiments, the spectral data may be generated by any suitable method, such as one or more of the methods described above. The molecule to be analyzed may be provided in a solution with solutes, such as water or DO, if desired. The concentration of the molecule to be analyzed in the solution is preferably in a range that provides a strong signal from the molecule relative to any signal from solutes (e.g., water) or other components of the sample (i.e., a suitable signal-to-noise ratio), which may facilitate further analysis, as described herein. Typically, the concentration of a protein or peptide molecule that will provide a desired signal-to-noise ratio is related to and proportional to the size of the protein or peptide. The preferred concentration provides an adequate signal-to-noise ratio for analysis. For example, as further described herein, the sample may facilitate spectral analysis for the molecule of interest without the need to subtract spectra due to solutes (e.g., water or DO) or other components of the sample. For example, for an IgG or other protein of about 150 kD, the sample may contain a concentration of protein from about 50 mg / mL to about 150 mg / mL. The amount of protein can vary proportionally from this range up to the size of the protein of interest, for example, BSA, about 67 kD, can be analyzed at a concentration of about 25 mg / mL to about 75 mg / mL in solution. The sample can be provided into a cell having a path length. The path length can be longer for DO (e.g., 30-50 μm, preferably about 40 μm) and shorter for water (e.g., 4-12 μm).

[0040] According to some embodiments, the spectral analysis may be performed in stages, for example as illustrated in Figure 3. The process illustrated in Figure 3 may include steps performed as at least a part of the "2DCOS / 2DCDS analysis" step illustrated in Figure 2.

[0041] According to some embodiments, the protein sample is perturbed (thermally, chemically, pressure or acoustic properties), including dynamic fluctuations in the vibrational spectrum. In step 310, raw spectral data may be collected and / or analyzed. Spectral data may be acquired sequentially at regular temperature intervals. According to some embodiments, the data may be baseline corrected.

[0042] According to some embodiments, the spectral data may be used to determine the presence of aggregated forms of proteins, peptides or peptoids. To this end, the first spectrum is subtracted from the subsequent spectra to generate a dynamic spectrum. In step 320, a covariance (difference) spectrum may be generated by subtracting the first spectrum (24° C.) from the subsequent total spectrum. The resulting covariance (difference) spectrum contains positive and negative peaks, which are said to be in phase or out of phase with each other.

[0043] Notably, the process described herein does not require manual subtraction of water or other references (e.g., solutes) from the spectral data. Such manual subtraction is a very conscious step often encountered in protein spectral analysis. In fact, the process described herein generates difference spectral data that is set based on the perturbation of the sample of interest. The output of that data can then be used for further analysis. The spectral contribution of water is automatically subtracted by subtracting the first spectrum having the overlapping water band with the amide I band from all subsequent spectra.

[0044] In step 330, 2D IR correlation techniques may be applied to generate synchronous (step 340) and asynchronous (step 350) plots. For example, the spectral data may be Fast Fourier Transformed ("FFT") to generate a complex matrix from which an intensity matrix is ​​obtained through a cross-correlation product that generates the synchronous and asynchronous plots. Techniques for generating these plots will be discussed in more detail herein.

[0045] A synchronization plot represents the intensity changes that occur during a perturbation. On the diagonal of this plot are peaks or bands (known as autopeaks) that change throughout the spectrum. Off the diagonal are crosspeaks that show correlations between autopeaks, i.e., relationships between observed secondary structure changes. Synchronization plots can be used to correlate in-phase peak intensity changes or shifts.

[0046] In synchronous correlation spectra, autopeaks at the diagonal positions represent the degree of dynamic fluctuation of the spectral signal that induces the perturbation. Crosspeaks represent simultaneous changes in the spectral signal at two different wavenumbers, suggesting the onset of a link or association of intensity fluctuations. If the sign of a crosspeak is positive, the intensities at corresponding wavenumbers are increasing or decreasing together. If the sign is negative, one is increasing while the other is decreasing.

[0047] Asynchronous plots include only cross peaks that are used to determine the order of events and the aggregation mechanism of the protein. Asynchronous plots can be used to correlate peak intensity changes or shifts of different phases.

[0048] In an asynchronous correlation spectrum, cross peaks appear only if the intensities change out of phase with respect to some Fourier frequency components of the signal fluctuations. If the intensity change at wavenumber ν2 occurs before wavenumber ν1, the sign of the cross peak is positive. If the intensity change at wavenumber ν2 occurs after wavenumber ν1, the sign of the cross peak is negative. If the same asynchronous cross peak positions, translated into a synchronous plot, populate the negative region (Φ(ν1,ν2)<0), the above sign convention is reversed.

[0049] 2D IR correlation enhances the spectral resolution of peaks underlying broad bands, such as the amide I and II bands, by broadening the peaks in two dimensions. These plots are symmetrical in nature, and for discussion, we refer to the upper triangle for the analysis. The synchronous plot (shown in 340) encompasses two types of peaks: (a) autopeaks, which are positive peaks on the diagonal, and (b) crosspeaks, which are off-diagonal peaks that can be either positive or negative. The asynchronous plot (shown in 350) consists only of crosspeaks relating out-of-phase peaks. As a result, this plot reveals a greater spectral resolution enhancement. The following rules may be applied to establish the order of molecular events: I. If an asynchronous crosspeak v2 is positive, v2 is perturbed before v1 (v2→v1). II. If the asynchronous crosspeak ν2 is negative, ν2 is perturbed after ν1 (ν2←ν1). III. If the synchronous crosspeaks (off-diagonal peaks, not shown in FIG. 3) are positive, then the asynchronous plots are only used (Rules I and II) to establish the order of events. IV. If the synchronous plot contains a negative crosspeak and the corresponding asynchronous crosspeak is positive, the order is reversed. V. If the synchronous plot encompasses a negative crosspeak and the corresponding asynchronous crosspeak is negative, then order is maintained.

[0050] A sequence of events can be established for each peak observed on the v2 axis. A table summarizing the sequence for each event can be provided. In step 360, a plot of the sequence of events is generated using the table summarizing the sequence of each event. At the top of each step (event) is the spectroscopic information of the cross-peak v2, while at the bottom of each step is the corresponding peak assignment or biochemical information of each event in perturbed sequence as a function of temperature. Examples are provided herein.

[0051] Two-dimensional correlation spectroscopy ("2DCOS") analysis can be used to resolve complex bands, such as the amide I band. An example of 2DCOS analysis is described in U.S. Patent No. 8,268,628, which is incorporated herein by reference. Those skilled in the art are directed to Isao Noda, "Two-dimensional co-distribution spectroscopy to determine the sequential order of distributed presence of species," Journal of Molecular Structure, No. 1069, pages 51-54, which describes an algorithm suitable for use in 2DCOS analysis.

[0052] The outline of the development of 2DCOS is as follows. j ,t k ) can be obtained for a system measured under the influence of external perturbations that induce changes in the observed spectral intensities. j can be, for example, a wave number, a frequency, a scattering angle, etc., and the other variable t k represents the effect of applied perturbations, e.g., time, temperature, and potential. l and m Only sequentially collected spectral data sets acquired during the observation interval between will be used in the 2DCOS analysis. For convenience, wavenumber and time are designated as the two variables used herein, although it will be understood that the use of other physical variables is also valid.

[0053] The dynamic spectrum used in 2D correlation spectroscopy is clearly defined as follows.

[0054]

number

[0055]

number

[0056]

number

[0057]

number

[0058]

number

[0059]

number

[0060] The asynchronous spectrum Ψ(ν1,ν2) represents the out-of-phase, or time-dependent, evolution of the spectral intensity. When (ν1,ν2)=0, the spectral intensity fluctuations at the two wavenumbers ν1 and ν2 are perfectly synchronized. When Φ(ν1,ν2) and Ψ(ν1,ν2) have the same sign, the overall spectral intensity fluctuations observed at ν1 mainly occur before the overall spectral intensity fluctuations observed at ν2. When the signs are different, the order is reversed. Finally, when Φ(ν1,ν2)=0, the order of the intensity fluctuations cannot be determined. It is important to emphasize that the 2D correlation spectrum only gives the order of the spectral intensity fluctuations, and not the order of the presence of the distributed species that are responsible for the spectral signal.

[0061] Referring again to FIG. 3, in step 370, the co-distribution correlation plot provides perturbed regions of protein population distribution (threshold 80%) in solution. Two-dimensional co-distribution spectroscopy ("2DCDS") analysis can be used to analyze populations of protein molecules in solution and how different populations of these proteins behave. Those skilled in the art are directed to "Two-dimensional co-distribution spectroscopy to determine the sequential order of distributed presence of species" by Isao Noda in Journal of Molecular Structure, issue 1069, pages 54-56, which describes an algorithm suitable for use in 2DCDS analysis.

[0062] The time-averaged spectrum given by equation (2)

[0063]

number

[0064]

number

[0065]

number

[0066]

number

[0067]

number

[0068]

number

[0069]

number

[0070]

number

[0071]

number

[0072]

number

[0073] Combining equations 6, 7 and 9 gives the equation for the asynchronous co-distribution spectrum as follows:

[0074]

number

[0075]

number

[0076]

number

[0077]

number

[0078] 2DCDS can provide elements of the aggregation mechanism in proteins or any process that is being investigated in a weighted manner. 2DCDS can be used to directly provide the sequence of species present distributed along the variable axis of perturbation (e.g., time, temperature, concentration, pressure, etc.). The technique can be used as a complementary tool to extend 2DCOS analysis in directly identifying the presence of intermediate species. According to some embodiments, perturbation-dependent spectra are acquired sequentially during the observation interval. 2D correlation spectra (synchronous and asynchronous spectra) are derived from the fluctuations of the spectra. Synchronous co-distribution intensity is measured as the coexistence or overlap of two separate spectral intensity distributions along the perturbation axis. Asynchronous co-distribution intensity is measured as the difference between the distributions of the two spectral signals. For cross-peaks with a positive sign, i.e., Δ(ν1,ν2)>0, the presence of the spectral intensity of ν1 is mainly distributed at an earlier stage along the time axis compared to that for ν2. On the other hand, if Δ(ν1,ν2)<0, the order is reversed. When Δ(ν1,ν2)≈0, the average distributions of the spectral intensities observed at the two wavenumbers during the time course are similar.

[0079] The difference between 2DCOS analysis is that it provides a path-averaged description of the perturbation process and its effect on the sample, whereas 2DCDS analysis provides weighted factors within a population of molecules (proteins) during the perturbation process. The results of 2DCOS and 2DCDS are a direct and concise description of the factors that are changing in the spectral data due to the perturbation.

[0080] According to some embodiments, for example as shown in FIG. 4, a system for performing data analysis may include at least the components shown to perform the functions of the methods described herein. Acquired data may be provided to one or more computing units, including a processor, for analysis. Modules may be provided to perform or manage the analysis of the data. Such modules may include a correlation analysis module, a visual model generator module, and / or a human interaction module. The modules may communicate with each other. In some embodiments, the modules may be implemented in software (e.g., subroutines and code). For example, the modules may be stored in memory and / or data storage and executed by a processor. In some aspects, some or all of the modules may be implemented in hardware (e.g., application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), programmable logic devices (PLDs), controllers, state machines, gate logic, discrete hardware components, or any other suitable devices), firmware, software, and / or combinations thereof. Additional features and functions of these modules according to various aspects of the subject technology are further described in this disclosure.

[0081] According to some embodiments, a method may be implemented to validate and prepare acquired data, for example as shown in Figure 5. The type of data is identified and validated. Based on the validation, the data may be converted and / or stored or rejected, and errors may be displayed to the user.

[0082] According to some embodiments, a method of analyzing acquired data may be performed, for example as shown in Figure 6. The type of data is verified for proper signal to noise ratio against a threshold. Based on the verification, the data may be subjected to a smoothing filter process prior to analysis or analysis.

[0083] According to some embodiments, for example as shown in FIG. 6, the data may be analyzed with operations including applying baseline correlation, locating peaks, calculating data windows, calculating correlations, calculating co-distributions, and / or calculating perturbation correlations.

[0084] Data manipulation may include automatic recognition of regions of interest (ROI) to identify particulates and solutions. Particulate size and number may be determined to confirm particulate population distribution. Data manipulation may be performed to ensure compliance with signal-to-noise ratio determinations, baseline corrections, etc., to determine water vapor content, and to determine signal strength of elements of interest within the spectral region being investigated. Data output for statistical analysis may be simplified using, among other things, a design of experiments approach. Intensities and spectral positions of elements of interest may be output as comma-separated files (*.csv). Covariance, i.e., dynamic spectral data sets may be generated based on perturbations of the sample of interest, the output of which may be used for further analysis. For example, data output may be provided in a format that facilitates integration with other bioanalytical results for comparability assessment, and is attributed by perturbation type, excipient, protein therapeutic, protein concentration, temperature, date of acquisition, and / or bioanalytical technique. This approach would allow for statistical analysis to be performed on all of the experiments performed under similar conditions. More importantly, the results of the DOE analysis would be a standalone document ready for final reporting and decision making.

[0085] According to some embodiments, the methods and systems described herein may apply a correlation function to the covariance or dynamic spectral data to generate two plots (synchronous and asynchronous), which algorithm is referred to as 2D IR correlation spectroscopy. Changes in the spectral data (e.g., peak intensities) that are in phase with each other may be correlated with each other as obtained in the synchronous plot. The elements that change in the spectral data may be determined. The overall maximum intensity change in the spectral data may be determined. The overall minimum intensity change in the spectral data may be determined. The minimum number of underlying spectral contributions in broad bands, such as amide bands in proteins and peptides, may be determined for curve-fitting analysis, which allows for the determination of secondary structure composition. The resolution of the spectral region being investigated may be enhanced, especially for broad bands of the spectrum.

[0086] The changes in the spectral data that are out of phase with each other (e.g., peak intensity) can be correlated as obtained in the asynchronous plot. The asynchronous plot also includes the sequence of events that describes the behavior of the protein in molecular detail. Detailed evaluation of the plot can be performed to confirm the sequence of events. Alternatively or in combination, this process can be automated. A joint variance function can be applied to the covariance or dynamic spectral data to generate a fused asynchronous plot that can be directly interpreted to determine the sequence of events. This method can alternatively be used to confirm the above interpretations of the description of the molecular behavior of the protein, which is a complex description. Inputting additional information to the curve fitting routine, namely, the number position and intensity information to the curve fitting routine, can also be an automated process to obtain the secondary structure composition of the protein and the range of protein aggregated species in the analyzed sample. The intensity information from the 2D IR correlation plot can be used to quantitatively determine oxidation products, such as deamination. For example, deamination can be detected on the lateral chin. Such analysis can be used in candidate drug selection or during protein design phases. As a long-term solution to the complexity of attributes that need to be correlated and resolved, machine learning approaches may be implemented.

[0087] According to some embodiments, analysis of the acquired data can be performed in a step-wise manner to provide a statistically valid, informative, and comprehensive solution for protein aggregation investigation, as shown, for example, in FIG. 7. According to some embodiments, the process illustrated in FIG. 7 can represent an application of the process illustrated in FIG. 3. QCL infrared microscopy results (top left of FIG. 7) are shown with initial and final QCL spectra at a low temperature of 5° C. (with a larger maximum) and a high temperature of 90° C. (with a smaller maximum) for H→D (hydrogen→deuterium) exchanged full-length IgG (150 KDa) in the spectral region 1700-1500 cm. -1 Amide I' (1700-1600cm -1 , mainly due to the peptide bond carbonyl stretching mode) and side chain (1600–1500 cm as defined in Table 1) -1 ) band differences are observed. Table 1: Amino acids as internal probes in DO

[0088] [Table 1] Subtracting the initial spectrum at low temperature from all subsequent spectra reveals the spectral changes due to increasing temperature (revealing changes in protein behavior), which are referred to as covariance spectral data, but are also often referred to as difference spectra. A cross-correlation function is then applied to these spectral changes to determine the relationship between the observed peaks. Two plots are generated, a synchronous and an asynchronous plot, which provide the correlation between the resulting peaks observed upon perturbation of the protein sample. These plots provide a wealth of molecular information and the sequence of molecular events that describe the behavior of the protein. A synchronous plot (bottom left of FIG. 7 ) is shown containing an autopeak (peak on the diagonal) along with the aggregation peak. This figure represents the maximum intensity change of the protein, and two additional autopeaks with lower intensity changes are observed. The relationship between these peaks is determined based on the observation of crosspeaks (peaks off the diagonal), which are either positive or negative, providing the relationship between the different autopeaks observed on the diagonal (i.e., the change in intensity due to subtraction of the initial spectrum). In this hypothetical case, the observed relationship leads to an aggregation event involving the helical secondary structure of the protein, which is confirmed by the presence of, for example, a tyrosine residue found within this helical motif, which serves as an internal probe for the protein aggregation process. The tyrosine peak then defines the region of the protein that is aggregating. 2DCOS analysis provides valuable detailed molecular information that was previously unavailable by other orthogonal techniques such as SEC, DSC and DLS. The results obtained from QCL are highly reproducible and have been rigorously tested using statistics. The QCL infrared spectral region is highly selective and sensitive, thus allowing not only conformational changes of the protein but also 6 of the 20 amino acid side chain vibrational modes (see Table 1) to be simultaneously investigated. Example 1 A developability and comparability assessment was performed for the three antibody drug conjugate fragments (Figure 8A-B). The analysis involved a total of 47 experiments. QCL microscopy was used to acquire images of 43 DOE conditions, 16 of which involved a comparison of three ADC fragments, designated ADC0, ADC1 and ADC2, in HEPES buffer at pH 6.6 and T = 24-30 °C. ADC2 was found to be free of aggregates under the conditions investigated, while ADC1 showed some aggregate species, but when heated to 28 °C, the aggregates returned to solution (Figure 9A-B). Additionally, aggregate species were present in the candidate ADC0, but increasing the temperature increased the presence of aggregate species. These aggregate species were determined to be ADC0. Similar results were seen for ADC1 using 2DCDS analysis (Figure 10).

[0089] Spectral analysis of aggregate-free ADC2 was also performed in the presence of different excipients (sucrose and NaCl) at approximately room temperature, T = 24-26 °C (Figure 11A-B). The value of judging the reproducibility of the analysis was increased by selecting different regions of interest (ROIs) (Figure 11A), as shown boxed in the QCL image analyzed without a spectrometer (Figure 11B). The sucrose excipient has a peak at 1420-1520 cm -1 In addition, the amide I' band and the side chain band (1520-1700 cm -1 ) are also shown, demonstrating the high sensitivity and selectivity of the method. Further evidence is shown in Figures 12A-C. Analytical wise, the ability to directly detect both excipients and protein therapeutics will be of great value to the biopharmaceutical industry, as it will be possible to corroborate the presence of excipients in each formulation. The HT-DCA platform will provide both valuable molecular information of the constituents within the samples, as well as the precision and reproducibility required for statistical analysis.

[0090] A full factorial design of 516 spectra and normal distribution analysis was performed for 43 experiments using a QCL microscope (QCL) under different conditions. The QbD experimental setup was such that 324 spectral data were analyzed to represent the evaluation of ADC2 in the presence of different amounts of NaCl, sucrose, and different percentages of both excipients (i.e., NaCl and sucrose). Sample sizes were determined to be n=8-12 by standard deviation. A developability and comparability assessment was pursued with ADC2, and below is a summary of the results obtained at 15, 30 and 60% sucrose at 26° and 28°C. Similar results were obtained for different concentrations of NaCl (325, 350 and 400 mM) and different percentages of sucrose and NaCl as excipients. Typically, the obtained results converged to a p-value greater than 0.8 (Figure 13). The distribution analysis was followed by a DOE statistical evaluation using stepwise full model fitting, ending with the AIC and BIC models arriving at the same outcome: 18.5% sucrose was the best excipient for ADC2 (Figures 14, 15).

[0091] The QCL spectral analysis capability of the HT-DCA platform provides further molecular characterization and stability assessment of protein therapeutics. This type of analysis is highly informative and allows for optimal design of protein therapeutic candidates. Two types of correlation analysis, 2DCOS analysis and 2DCDS analysis, were performed to provide information on the behavior of protein therapeutics in solution.

[0092] The conceptual analysis of 2D IR correlation plots was applied to infrared spectra of proteins. The amide I' bands and side chain bands consist of broad, underlying contributions, whether conformationally sensitive, like carbonyl stretching within peptide bonds or side chain vibrational modes, that provide information of the neighboring environment and weak interactions. To extract this information, a covariance spectrum is generated by subtracting a reference spectrum from the entire spectrum that follows. For example, in a protein thermal denaturation study (temperature perturbation), an initial spectrum at low temperature would be used for subtraction. The generated covariance spectrum contains the intensity change with increasing temperature. A correlation function is then applied to the data set that will relate the intensity change observed in the covariance spectrum, which is in the form of two separate graphs, with increased resolution. These plots can resolve highly overlapping bands, validate more flexible regions of a protein, decipher protein aggregation mechanisms, and validate protein-target interactions. 2D IR correlation plots are called synchronous and asynchronous plots. These plots are symmetrical in nature, and for interpretation, we refer to the top half of each plot. The sync plot has positive peaks on the diagonal, known as autopeaks. Autopeaks encompass the overall change in intensity observed for the entire spectral data set. The magnitude of the change can be identified and used to determine the flexibility or sensitivity that regions of the protein may have to perturbations. The location and number of these peaks are used to determine the underlying spectral contributions to the amide I' band and the side chain bands (see Table 2). Table 2: Summary of band assignments for ADC2 in 15% sucrose in HEPES buffer.

[0093] [Table 2] Synchronous plots also have off-diagonal peaks known as cross-peaks. These cross-peaks are used to determine the relationship of the autopeaks. The cross-peaks observed in a synchronous plot are due to intensity changes that are in phase with each other. One can consider two peaks that change in intensity incrementally or vice versa, and these two autopeaks will have an associated cross-peak that represents their relationship to each other (Figures 16A-B).

[0094] The non-synchronous plot does not include peaks on the diagonal, but depicts enhanced spectral resolution. The resulting cross-peaks are due to peaks that vary in phase with each other differently due to their intensity in the covariance spectrum, thus providing more information. Among them is the order of molecular events due to thermal perturbations. Cross-peaks in the non-synchronous plot can be either positive or negative, and the order can be determined. In general, if the sign of the cross-peak is positive in both plots, the order defined in the non-synchronous plot is preserved. As a result, a positive cross-peak means v1 occurs before v2. This interpretation is specified as true if and only if the same cross-peak in the synchronous plot is also positive. However, if the sign of the cross-peak is different in both plots, the order is reversed.

[0095] Applying this to the plots in Figures 16A-B, we see that the cross peak in the asynchronous plot is positive at (1652, 1632). -1 The (ν1) peak is at 1632 cm -1 In molecular theory, the π-helix would be perturbed before the antiparallel β-sheet in the protein (Table 2). Similarly, the β-turn (hinge loop, 1670.3 cm -1) is perturbed before the antiparallel β-sheet. Furthermore, these plots were used to determine how sucrose stabilized ADC2 in solution. Hydrogen bonds between the side chains and sucrose stabilized the β-turn (hinge loop) and therefore the β-sheet. More importantly, the molecular changes that occurred in the protein fragment of interest are shown in Figure 17.

[0096] Although the temperature perturbations were limited to near room temperature, the analysis still allowed the determination of H-bonding interactions between the side chains and their aqueous environment with the excipient (sucrose), and these interactions stabilized the secondary structure of ADC2.

[0097] 2DCDS analysis proved useful for assessing the kinetics of protein solutions and distribution of conformational dynamics within a temperature range, in this case a small temperature range of only 26-28 °C for ADC2 in HEPES buffer with 15% sucrose (Figure 18A-B). Interpretation of asynchronous codistribution plots is straightforward when compared to 2D IR correlation. Comparison of crosspeak signs between plots is not necessary. For positive crosspeaks, it can be determined that ν1 occurs before ν2. Furthermore, for negative crosspeaks, it can be determined that ν2 occurs before ν1.

[0098] No aggregation was observed for this protein. Referring to the asynchronous plot (FIG. 18B), for this protein in solution, a β-turn, also called a hinge loop (1660 cm -1 ) and negatively charged aspartate (1553 cm -1 ) and glutamic acid (1543cm -1) residues, which is consistent with their location within the β-turn motif of ADC2. 2DCOS and 2DCDS analyses allowed a complete description of ADC2 and the stabilizing effect of sucrose on ADC2 at the molecular level (Figures 16A-18B). In summary, the main stabilizing feature in ADC2 was that of the hinge loop due to salt-bridge interactions observed between arginine and nearby asparagine residues. Disruption of the salt-bridge interaction was prevented by a second disulfide bridge introduced by site-directed mutagenesis. Further stabilization was achieved by formulation conditions that included sucrose as an excipient. Specifically, 15% sucrose also provided stabilization by H-bonding with these same residues. Table 3: Summary of curve fitting results showing the secondary structure composition of ADC Fragment 2 at 26°C.

[0099] [Table 3] FIG. 19 shows plots corresponding to the results shown in Table 3. Example 2 A sample containing National Institute of Standards and Technology Reference Material 8671 (RM8671), lot number 14HB-D-002m, humanized IgG1κ monoclonal antibody (NIST mAb) in HO was investigated for analysis according to the methods described herein. The sample was added to a cell on a CaF2 slide for data acquisition using a QCL microscope. The perturbations applied were temperatures ranging from 24 to 60 °C at 4 °C intervals. QCL IR spectral data was collected using a 4 cm -1 The data were acquired using a 4x objective at 0.5cm -1 were coded and baseline corrected.

[0100] NIST mAb standard is IgG1 κ The amino acid sequences of the heavy chain (SEQ ID NO:5) and the light chain (SEQ ID NO:6) of the antibody are shown below.

[0101] [ka] Amino acid side chain assignments for the samples are provided in Tables 4 and 5. Table 4: Heavy amino acid side chain assignments for NIST mAb in HO

[0102] [Table 4] Table 5: Light Amino Acid Side Chain Assignments for NIST mAb in HO

[0103] [Table 5] As shown in FIG. 20A, in the MID IR spectral region 1750-1400 cm -1 QCL spectra of NIST mAb (50 mg / mL) at 20° C. were acquired in HO at temperatures ranging from 24 to 60° C. FIG. 20A shows the overlaid spectra showing the amide I, II, and III bands. Based on the spectral data, synchronous (FIG. 20B) and asynchronous (FIG. 20C) 2D IR correlation plots were generated. Overlapping HO absorbance was observed in the amide I band, but not in the amide II and III bands, suggesting that sufficient protein concentration was achieved for analysis. The method applied according to the embodiments of the present disclosure eliminates the need for the user to consciously manipulate HO or subtract a baseline.

[0104] As shown in FIG. 21A, in the MID IR spectral region 1750-1500 cm -1 QCL spectra of NIST mAb (50 mg / mL) at 200 C were acquired in HO within the temperature range of 24-60 °C. Figure 21A shows the overlaid spectra showing both amide II and III bands. The spectral data are based on synchronous (Figure 21B) and asynchronous (Figure 21C) plots. Correlation between the amide I and II bands is demonstrated. Enhanced resolution is achieved through the use of asynchronous plots.

[0105] Peak assignments for NIST mAb (50 mg / mL) in HO are provided in Table 6. Table 6: Summary of peak assignments for NIST mAb (50 mg / mL) in HO

[0106] [Table 6] The sequence of events for NIST mAb (50 mg / mL) in HO under thermal stress within the temperature range of 24 to 60 °C is shown in Figure 22. -1 is 1692cm -1 The vibrational modes are most stable, and the 1618 cm -1 was also assigned to thermally induced protein aggregation at 60 °C based on this work. -1 may be assigned to an α-helix.

[0107] The order of events for NIST mAb in HO (50 mg / mL) is provided in Table 7. Table 7: Summary of sequence of events for NIST mAb (50 mg / mL) in HO

[0108] [Table 7] FIG. 23 shows an asynchronous 2D IR co-distribution analysis plot for NIST mAb (50 mg / mL) in HO under thermal stress in the temperature range of 24-60° C. Thermal stress is observed in the spectral region 1760-1380 cm for the temperature range 24-60° C. -1 of NIST mAb (50 mg / mL). This plot provides the most common response for a population of proteins in solution. As a result, in the case of NIST mAb (50 mg / mL), the thermal stress was related to the perturbation of glutamic acid with Arg, probably through salt-bridge interactions. Glutamic acid is hydrogen-bonded to His residues, and these residues are located in α-helices and β-sheets.

[0109] Figures 24A-D show an example of the automated analysis, providing (A) overlaid raw spectral data, 2D IR correlations, i.e., (B) synchronous and (C) asynchronous plots, and (D) relationships within the co-distribution asynchronous plot. The vertical dashed lines are provided during the automated analysis based on the absolute intensity values ​​of the autopeaks (positive peaks on the diagonal shown in Figure 24B) in the synchronous plot. Example 3 A sample containing bovine serum albumin ("BSA") in HO was investigated for analysis according to the methods described herein. The sample was added to a cell on a CaF2 slide for data acquisition using a QCL microscope. The perturbations applied were temperatures ranging from 24 to 60 °C at 4 °C intervals. QCL spectral data was collected at 4 cm -1 The data were acquired using a 4x objective at 0.5cm -1 were coded and baseline corrected.

[0110] Below is the amino acid sequence for BSA that was analyzed. (SEQ ID NO:7) Amino acid side chain assignments for the samples are provided in Table 8. Table 8: Amino acid side chain assignments for BSA in HO

[0111] [Table 8] As shown in FIG. 25A, in the MID IR spectral region 1750-1500 cm -1QCL spectra of BSA (40 mg / mL) at 20 °C were acquired in HO at temperatures ranging from 24 to 60 °C. Figure 25A shows the overlaid spectra showing the amide I and II bands. 2D IR correlation analysis plots were generated based on the spectral data synchronous (Figure 25B) and asynchronous (Figure 25C). Correlation between the amide I and II bands is demonstrated. Enhanced resolution is achieved through the use of the asynchronous plot. Additionally, the highest intensity autopeaks in the synchronous plot are due to helical perturbations to this globular protein. Additionally, no aggregation was observed.

[0112] Peak assignments for BSA (40 mg / mL) are provided in Table 9. Table 9: Summary of peak assignments for BSA (40 mg / mL)

[0113] [Table 9] The sequence of events for BSA (40 mg / mL) under thermal stress within the temperature range of 24-60° C. is shown in FIG. 26. The sequence of events for BSA (40 mg / mL) is also provided in Table 10. Table 10: Summary of sequence of events for BSA (40 mg / mL)

[0114] [Table 10] First, lysine (1530.0 cm -1 and 1525.5 cm -1 The helical region involved in the salt-bridge interaction with -1 ) located within the aspartate (1567cm -1 ) and glutamate (1584cm -1 ), followed by β-sheet (1629.6 cm -1 ) and then the antiparallel β-sheet (1629.6 cm -1 )β turn (1698cm -1 ) in tyrosine (1518cm -1) and histidine (1606.5 cm -1 ) is perturbed. Finally, at high temperature, the β-turn (1684.0 cm -1 ) located close to glutamate (1560cm -1 ) and aspartate (1576.4 cm -1 ), which perturbs the salt bridge interaction involving arginine.

[0115] Figure 27 shows the temperature range of 24 to 60 °C and the spectral region of 1750 to 1380 cm -1 Figure 2 shows asynchronous 2D IR codistribution analysis plots for BSA (40 mg / mL) in HO under thermal stress in which the thermal stress was associated with perturbation of glutamates in the β-turn and helix regions. Example 4 A sample containing a mixture of NIST mAb and BSA in HO was investigated for analysis according to the methods described herein. The sample was added to a cell on a CaF2 slide for data acquisition using a QCL microscope. The perturbations applied were temperatures ranging from 24 to 60 °C at 4 °C intervals. QCL spectral data was collected using a 4 cm -1 The data were acquired using a 4x objective at 0.5 cm -1 were coded and baseline corrected.

[0116] As shown in Figure 28A, in the spectral region 1750-1500 cm -1 QCL spectra of NIST mAb / BSA (1:2 molar ratio) mixtures at 20°C were acquired in HO at temperatures ranging from 24 to 60°C. Figure 28A shows the overlaid spectra showing the amide I and II bands. Based on the spectral data, synchronous (Figure 28B) and asynchronous (Figure 28C) 2D IR correlation plots were generated. The contours of the overall synchronous plots show distinguishable features of both the NIST mAb and the BSA pure components.

[0117] NIST mAb / BSA peak assignments are provided in Table 11. Table 11: NIST mAb / BSA peak assignment summary

[0118] [Table 11] Example 5 A sample containing lysozyme in HO was investigated for analysis according to the method described herein. A cell on a custom-made CaF2 slide was used with a 7 μm path length for the sample in HO. The applied perturbation was temperature in 4°C intervals ranging from 24 to 60°C. QCL IR spectral data was collected using a 4 cm -1 The data were acquired using a 4x objective at 0.5cm -1 were coded and baseline corrected.

[0119] The analyzed amino acid sequence of lysozyme is shown below. KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPCSALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL (SEQ ID NO:8) Amino acid side chain assignments for the samples are provided in Table 12. Table 12: Amino acid side chain assignments for lysozyme in HO

[0120] [Table 12] As shown in Figure 29A, in the spectral region 1750-1500 cm -1QCL spectra of lysozyme (600 mg / mL) at 200 C were acquired in HO at temperatures ranging from 24 to 60 °C. Figure 29A shows the overlaid spectra showing the amide I and II bands. Based on the spectral data, synchronous (Figure 29B) and asynchronous (Figure 29C) 2D IR correlation plots were generated. Correlations between the helical regions of the protein and the β-turns can be evidenced by thermal stress. Weak interactions between glutamate, aspartate and arginine, lysine and histidine residues are also important for the stability of lysozyme, as evidenced by the correlations observed in both the synchronous and asynchronous plots. No aggregation was observed for this protein.

[0121] Peak assignments for lysozyme (600 mg / mL) are provided in Table 13. Table 13: Summary of peak assignments for Lysozyme (600 mg / mL)

[0122] [Table 13] The sequence of events for lysozyme (600 mg / mL) under thermal stress within the temperature range of 24-60° C. is shown in FIG. 30. The sequence of events for BSA (40 mg / mL) is also provided in Table 14. Table 14: Summary of sequence of events for Lysozyme (600 mg / mL)

[0123] [Table 14] First, tyrosine (1514.6 cm -1 ) and lysine (1526.9 cm -1 ), followed by arginine (1628.7 cm -1 ), then the β-sheet (1637.2 cm -1 ), and then glutamate in the β-sheet (1536.8 cm -1 ), followed by the helical region (1647.0 cm -1 ) and β-turn (1698.0 cm -1and 1683.8 cm -1 ) located in the glutamate (1556cm -1 ), followed by glutamate (1547.8 cm -1 ), hinge loop (1660.5cm -1 ), followed by aspartate (1566.1, 1672.3 cm -1 ), and a single histidine (1596.6 cm ) located near the N-terminus that likely interacts with aspartate through H-bond interactions. -1 ) and finally, all of Arg, Asn, and Gln are perturbed (1666.6 cm -1 ). No aggregation was observed.

[0124] Figure 31 shows the temperature range of 24 to 60 °C and the spectral region of 1750 to 1500 cm -1 Asynchronous 2D IR codistribution plots for lysozyme (600 mg / mL) in HO under thermal stress in. For lysozyme (600 mg / mL), the thermal stress involved perturbations of tyrosines located in the hinge loops, and lysines and glutamates located near or in β-turn and helix regions.

[0125] 32 is a block diagram illustrating an example computer system that may implement a computing device (e.g., of FIG. 4). In an embodiment, computer system 1900 may be implemented using hardware or a combination of software and hardware, either in a dedicated server or integrated into another entity or distributed across multiple entities.

[0126] Computer system 1900 includes a bus 1908 or other communication mechanism for communicating information, and a processor 1902 coupled with bus 1908 for processing information. By way of example, computer system 1900 may be implemented with one or more processors 1902. Processor 1902 may be a general purpose microprocessor, a microcontroller, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), a programmable logic device (PLD), a controller, a state machine, gate logic, discrete hardware components, and / or any other suitable entity capable of performing calculations or other manipulations of information.

[0127] Computer system 1900 may include, in addition to hardware, code that creates an execution environment for such computer programs, such as code constituting processor firmware, a protocol stack, a database management system, an operating system, or a combination of one or more of these stored in included memory 1904, such as random access memory (RAM), flash memory, read only memory (ROM), programmable read only memory (PROM), erasable PROM (EPROM), registers, hard disk, removable disk, CD-ROM, DVD, and / or any other suitable storage device coupled to a bus 1908 that stores information and instructions executed by processor 1902. Processor 1902 and memory 1904 may be supplemented by, or incorporated in, special purpose logic circuitry.

[0128] The instructions may be stored in memory 1904 and implemented in one or more computer program products, i.e., one or more modules of computer program instructions encoded on a computer-readable medium for execution by or to control the operation of computer system 1900, according to any manner familiar to those skilled in the art, including but not limited to computer languages ​​such as data-oriented languages ​​(e.g., SQL, dBase), system languages ​​(e.g., C, Objective-C, C++, Assembly), architecture languages ​​(e.g., Java®, NET), and / or application languages ​​(e.g., PHP, Ruby, Perl, Python). The instructions may also be implemented in a computer language, such as an array language, an aspect-oriented language, an assembly language, an authoring language, a command line interface language, a compiled language, a concurrent language, a curly-bracket language, a dataflow language, a data structure language, a declarative language, an esoteric language, an extensible language, a fourth generation language, a functional language, an interactive mode language, an interpreted language, an iterative language, a list-based language, a little language, a logic language, a machine language, a macro language, a metaprogramming language, a multi-paradigm language, numerical analysis, a non-English based language, an object-oriented class-based language, an object-oriented prototype-based language, an offside rule language, a procedural language, a self-reflective language, a rule-based language, a scripting language, a stack-based language, a synchronization language, a syntax processing language, a visual language, a wirth language, and / or an xml-based language. The memory 1904 may also be used for storing temporary variables or other intermediate information during execution of instructions to be executed by the processor 1902.

[0129] A computer program as discussed herein does not necessarily correspond to a file in a file system. A program may be stored as part of a file that holds other programs or data (e.g., one or more scripts stored in a markup language document), in a single file dedicated to the program, or in multiple cooperating files (e.g., a file that stores one or more modules, subprograms, or portions of code). A computer program may be deployed to be executed on one computer, or on multiple computers that are located at one site or distributed across multiple sites and interconnected by a communications network. The processes and logic flows described herein may be implemented by one or more programmable processors executing one or more computer programs, which perform functions by operating on input data and generating output.

[0130] The computer system 1900 further includes a data storage device 1906, such as a magnetic or optical disk, coupled to the bus 1908 for storing information and instructions. The computer system 1900 may be coupled to various devices (e.g., devices 1914 and 1916) via an input / output module 1910. The input / output module 1910 can be any input / output module. Exemplary input / output modules 1910 include data ports (e.g., USB ports), audio ports, and / or video ports. In some embodiments, the input / output module 1910 includes a communication module. Exemplary communication modules include network interface cards, such as Ethernet cards, modems, and routers. In an aspect, the input / output module 1910 is configured to connect to multiple devices, such as input devices 1914 and / or output devices 1916. Exemplary input devices 1914 include a keyboard and / or a pointing device (e.g., a mouse or trackball) through which a user may provide input to the computer system 1900. Other types of input devices 1914, such as tactile input devices, visual input devices, audio input devices, and / or brain-computer interface devices, may also be used to provide interaction with the user. For example, feedback provided to the user can be any form of sensory feedback (e.g., visual feedback, audio feedback, and / or tactile feedback), and input from the user may be received in any form, including acoustic, speech, tactile, and / or brainwave input. Exemplary output devices 1916 include display devices, such as cathode ray tube (CRT) or liquid crystal display (LCD) monitors, that display information to the user.

[0131] According to an embodiment, a client device and / or a server may be implemented using the computer system 1900 in response to the processor 1902 executing one or more sequences of one or more instructions contained in the memory 1904. Such instructions may be read into the memory 1904 from another machine-readable medium, such as a data storage device 1906. Executing the sequences of instructions contained in the memory 1904 causes the processor 1902 to perform the process steps described herein. One or more processors in a multi-processing arrangement may also be used to execute the sequences of instructions contained in the memory 1904. In some embodiments, hardwired circuitry may be used in place of or in combination with software instructions to implement various aspects of the present disclosure. As such, aspects of the present disclosure are not limited to any specific combination of hardware circuitry and software.

[0132] Various aspects of the subject matter described herein may be implemented in a computing system including back-end components (e.g., a data server), or in a computing system including middleware components (e.g., an application server), or in a computing system including front-end components (e.g., a client computer having a graphical user interface and / or a web browser through which a user may interact with an implementation of the subject matter described herein), or in any combination of one or more such back-end, middleware, or front-end components. The components of system 1900 may be interconnected by any form or medium of digital data communication (e.g., a communications network). Examples of communications networks include local area networks and wide area networks.

[0133] The terms "machine-readable storage medium" or "computer-readable medium" as used herein refer to any one or more media that participate in providing instructions to the processor 1902 for execution. Such media may take many forms, including but not limited to non-volatile media, volatile media, and transmission media. Non-volatile media include, for example, optical or magnetic disks, such as the data storage device 1906. Volatile media include dynamic memory, such as the memory 1904. Transmission media include coaxial cables, copper wire and fiber optics, including the wires that comprise the bus 1908. Common forms of machine-readable media include, for example, a floppy disk, a flexible disk, a hard disk, a magnetic tape, any other magnetic medium, a CD-ROM, a DVD, any other optical medium, punch cards, paper tape, any other physical medium with a pattern of holes, a RAM, a PROM, an EPROM, a FLASH EPROM, any other memory chip or cartridge, or any other medium from which a computer can read. The machine-readable storage medium can be a machine-readable storage device, a machine-readable storage substrate, a memory device, a composition of matter effecting a machine-readable propagated signal, or a combination of one or more of them.

[0134] As used herein, a "processor" may include one or more processors, and a "module" may include one or more modules. In aspects of the subject technology, a machine-readable medium is a computer-readable medium that is encoded or stored with instructions, is a computer element, and defines structural and functional relationships between the instructions and the rest of the system, thereby enabling the functionality of the instructions to be realized. The instructions may be, for example, executable by the system or by a processor of the system. The instructions may be, for example, a computer program including code. The machine-readable medium may comprise one or more media.

[0135] As used herein, the term "module" refers to a set of software instructions or logic embedded in hardware or firmware, which may be written in a programming language such as C++ and may have entry and exit points. Software modules may be installed in a dynamic link library, compiled and linked into an executable program, or written in an interpreted language such as BASIC. It will be understood that software modules may be callable from other modules or the software module itself, and / or may be called in response to a detected event or interrupt. Software instructions may be embedded in firmware, such as an EPROM or EEPROM. It will be further understood that hardware modules may consist of connecting logic units, such as gates and flip-flops, and / or may consist of programmable units, such as programmable gate arrays or processors. The modules described herein are preferably implemented as software modules, but may be depicted as hardware or firmware.

[0136] It is contemplated that the modules may be combined into fewer modules. A module may also be separated into multiple modules. The described modules may be implemented as hardware, software, firmware, or any combination thereof. In addition, the described modules may reside in different locations connected by a wired or wireless network, or the Internet.

[0137] It will be understood that in general, a processor may include, by way of example, a computer, program logic, or other substrate configuration representing data and instructions that operate as described herein, hi other embodiments, a processor may include controller circuitry, processor circuitry, a processor, a general purpose single-chip or multi-chip microprocessor, a digital signal processor, an embedded microprocessor, a microcontroller, and the like.

[0138] It will further be appreciated that in one embodiment, program logic may be advantageously implemented as one or more components, which may be advantageously configured to execute on one or more processors, including, but not limited to, software or hardware components, modules such as software modules, object-oriented software components, class and task components, process methods, functions, attributes, procedures, subroutines, segments of program code, drivers, firmware, microcode, circuits, data, databases, data structures, tables, arrays, and variables.

[0139] The previous description is provided to enable one skilled in the art to practice the various configurations described herein. Although the subject technology has been specifically described with reference to various figures and configurations, it should be understood that the various figures and configurations are for illustration purposes only and should not be taken as limiting the scope of the subject technology.

[0140] There may be many other means of implementing the subject technology. The various functions and elements described herein may be divided differently from the functions and elements shown without departing from the scope of the subject technology. Various modifications to these configurations will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other configurations. Thus, many changes and modifications may be made to the subject technology by those skilled in the art without departing from the scope of the subject technology.

[0141] It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of example approaches. It is understood that the specific order or hierarchy of steps in the processes may be rearranged based on design preferences. Some steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.

[0142] As used herein, when any of a series of items are separated by the terms "and," "and," or "or," the phrase "at least one of" following the items modifies the entire list and not each member (i.e., each item) of the list. The phrase "at least one of" does not require the selection of at least one of each item in the list, but rather can mean including at least one of any of the items, and / or at least one of any combination of the items, and / or at least one of each of the items. By way of example, the phrase "at least one of A, B, and C" or "at least one of A, B, or C" refers to only A, only B, or only C, any combination of A, B, and C, and / or at least one of each of A, B, and C, respectively.

[0143] Terms such as "top," "bottom," "front," "rear," and the like, as used in this disclosure, should be understood to refer to any frame of reference other than the usual gravitational frame of reference, such that the top, bottom, front, and rear surfaces may extend upwards, downwards, diagonally, or horizontally in the gravitational frame of reference.

[0144] Furthermore, to the extent the terms "including," "having," or the like are used in this specification or the claims, such terms are intended to be non-exclusive in the same manner as the term "comprising" is interpreted when used as a transitional phrase in a claim.

[0145] The word "exemplary" is used herein to mean "serving as an example, instance, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments.

[0146] Elements described in the singular are intended to mean "one or more" rather than "one" unless otherwise specified. Masculine (e.g., his) pronouns include feminine and neuter (e.g., her or its) and vice versa. The terms "some" and "several" refer to one or more. Underlined and / or italicized headings and subheadings are used for convenience only and do not limit the subject art and shall not be referenced in connection with interpreting the description of the subject art. All structural and functional equivalents of the elements of the various configurations described throughout this disclosure that are known or that later become known to those skilled in the art are expressly incorporated herein by reference and are intended to be covered by the subject art. Furthermore, nothing disclosed herein is intended to be made public, whether or not expressly stated above.

[0147] Although certain aspects and embodiments of the subject technology have been described, they have been presented by way of example only and are not intended to limit the scope of the subject technology. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. The scope of the appended claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the subject technology. Exemplary embodiments 1. A method for processing data representative of properties of proteins, peptides and / or peptoids, comprising: acquiring spectral data for said protein, peptide and / or peptoid with respect to an applied perturbation; applying a two-dimensional co-distribution (2DCDS) analysis to generate an asynchronous co-distribution plot of said proteins, peptides and / or peptoids; identifying cross-peaks in said asynchronous co-distribution plot that correlate with autopeaks associated with aggregation of said proteins, peptides and / or peptoids; and using the cross-peaks to determine an order of occurrence of distributed spectral intensities with respect to the applied perturbation. 2. The step of using the cross peaks comprises: determining whether the cross peaks corresponding to two wave numbers v1 and v2 have positive values; and determining that when the cross peaks have positive values, the spectral intensities present at v1 fall within an interval of the applied perturbation that is lower than the interval within which the spectral intensities present at v2 fall. 3. The step of using the cross peaks comprises: determining whether the cross peaks corresponding to two wave numbers v1 and v2 have negative values; and determining that when the cross peak has a negative value, the spectral intensity present at v2 falls within an interval of the applied perturbation that is lower than the interval within which the spectral intensity present at v1 falls. 4. The method of embodiment 1, wherein the spectral data is FT-IR spectral data. 5. The method of embodiment 1, wherein the asynchronous codistribution intensity of the asynchronous codistribution plot is expressed as the difference in distribution of two spectral signals. 6. The method of embodiment 1, wherein the applied perturbation is time, temperature, concentration or pressure. 7. applying said two-dimensional co-distribution (2DCDS) analysis to generate a synchronous co-distribution plot of said proteins, peptides and / or peptoids; identifying a synchronous codistribution peak in said synchronous codistribution plot that is associated with aggregation of said protein, peptide and / or peptoid; and using the synchronous co-distribution peaks to determine an overlap of distribution patterns of spectral intensities with respect to the applied perturbation. 8. The method of embodiment 1, wherein using the synchronous co-distribution peak comprises determining, for two wavenumbers v1 and v2, whether the synchronous co-distribution peak corresponding to the two wavenumbers is within a range. 9. Applying two-dimensional correlation (2DCOS) analysis to generate synchronous and asynchronous correlation plots for said proteins, peptides and / or peptoids; identifying positive cross-peaks in the synchronous correlation plot that correlate with autopeaks associated with aggregation of said proteins, peptides and / or peptoids; and using the identified peak intensities of the spectral data to determine an amount of aggregation of the protein, peptide and / or peptoid. 10. The method of embodiment 9, further comprising the step of comparing the amount of aggregation of at least one of the proteins, peptides and peptoids with the order of occurrence of the distributed spectral intensities for the applied perturbation. 11. The method of embodiment 1, wherein the step of acquiring the spectral data comprises performing QCL infrared spectroscopy on a sample containing at least one of the protein, peptide and peptoid. 12. The method of embodiment 1, further comprising the step of recognizing regions of interest for discrimination between particulates and solutions. 13. The method of embodiment 1, further comprising determining the size and number of microparticles to ascertain the population distribution of said microparticles. 14. The method of embodiment 1, further comprising analyzing the spectral data to perform at least one of verifying the signal-to-noise ratio, performing a baseline correction, determining water vapor content, and determining signal strength within a spectral region. 15. The method of embodiment 1, further comprising generating covariance or dynamic spectral data based on perturbations of the sample. 16. The method of embodiment 1, further comprising a step of correlating changes, including peak intensities, in the spectral data that are in phase with one another as obtained in the synchronous plot. 17. The method of embodiment 1, further comprising determining factors that vary in the spectral data. 18. The method of embodiment 1, further comprising determining a maximum overall intensity change within the spectral data. 19. The method of embodiment 1, further comprising determining a minimum overall intensity change within the spectral data. 20. The method of embodiment 1, further comprising the steps of determining a minimum number of underlying spectral contributions in a band, performing a curve fitting analysis, and determining the secondary structure composition of the sample. 21. The method of embodiment 1, further comprising increasing the resolution of the spectral data. 22. The method of embodiment 1, further comprising a step of correlating changes, including peak intensities, in the spectral data that are out of phase with one another as obtained in the asynchronous plots. 23. The method of any one of the preceding claims, further comprising determining the presence and / or extent of deamination of amino acid side chains in said proteins, peptides and / or peptoids. 24. The method of any one of the preceding claims, further comprising determining the stability of a domain within said protein, peptide and / or peptoid. 25. A system for processing data representative of properties of at least one of proteins, peptides, and peptoids, comprising: a data acquisition module configured to acquire spectral data of said protein, peptide and / or peptoid with respect to an applied perturbation; applying a two-dimensional co-distribution (2DCDS) analysis to generate an asynchronous co-distribution plot of said proteins, peptides and / or peptoids; identifying cross-peaks in the asynchronous codistribution plot that correlate with autopeaks associated with aggregation of said protein, peptide and / or peptoid; and a correlation analysis module configured to use the cross-peaks to determine an order of occurrence of distributed spectral intensities with respect to the applied perturbation. 26. The system of embodiment 25, further comprising a visual model generator that generates one or more plots for display. 27. The system of embodiment 25, further comprising a human interaction module comprising a human interface. 28. The system of embodiment 25, wherein the data acquisition module comprises a quantum cascade laser microscope. 29. When executed by one or more computers, the one or more computers are acquiring spectral data for said protein, peptide and / or peptoid with respect to an applied perturbation; applying a two-dimensional co-distribution (2DCDS) analysis to generate an asynchronous co-distribution plot of said proteins, peptides and / or peptoids; identifying cross-peaks in the asynchronous codistribution plot that correlate with autopeaks associated with aggregation of said protein, peptide and / or peptoid; A non-transitory computer-readable medium comprising instructions for using the cross-peaks to determine an order of occurrence of distributed spectral intensities with respect to the applied perturbation.

Claims

1. 1. A method for processing data representative of at least one characteristic of a protein, peptide, and peptoid, comprising: applying a controlled perturbation to at least one of said proteins, peptides and peptoids in solution; using a Raman spectrometer and without the use of exogenous probes or additives, successively acquiring a plurality of spectral images of the at least one of the proteins, peptides and peptoids in the solution, the plurality of successively acquired spectral images capturing induced changes in spectral intensity as a function of the applied perturbation; identifying and selecting a region of interest in at least one of the acquired spectral images that is related to the applied perturbation; selecting and analyzing spectral data in the region of interest of the plurality of consecutively acquired spectral images, the spectral data including data about side chains of amino acids of at least one of the proteins, peptides and peptoids in the solution, the step of analyzing the spectral data including analyzing side chain modes of the at least one of the proteins, peptides and peptoids as an intrinsic probe; applying a two-dimensional co-distribution (2DCDS) analysis to generate an asynchronous co-distribution plot of at least one of said proteins, peptides and peptoids; and identifying at least one cross-peak in the asynchronous codistribution plot that correlates with an autopeak associated with aggregation of at least one of said proteins, peptides and peptoids.

2. The step of using the cross peaks comprises: Two wave numbers ν １ and ν ２ determining whether the cross peaks corresponding to the two wavenumbers have positive values ​​for When the cross peak has a positive value, v １ The spectral intensity present at ν ２ and determining that the spectral intensity distribution is within a period of the applied perturbation that is earlier than the period during which the spectral intensity distribution is present in the applied perturbation.

3. The step of using the cross peaks comprises: Two wave numbers ν １ and ν ２ determining whether the cross peaks corresponding to the two wavenumbers have negative values ​​for When the cross peaks have negative values, v ２ The spectral intensity present at ν １ and determining that the spectral intensity distribution is within a period of the applied perturbation that is earlier than the period during which the spectral intensity distribution is present in the applied perturbation.

4. The method of claim 1 , wherein the asynchronous codistribution strength of the asynchronous codistribution plot is expressed as a difference in distributions of two spectral signals.

5. The method of claim 1 , wherein the applied perturbation is a thermal, electrical potential, concentration, pressure, chemical reaction, agitation, oxidation, or acoustic perturbation.

6. applying said two-dimensional co-distribution (2DCDS) analysis to generate a synchronous co-distribution plot of at least one of said proteins, peptides and peptoids; identifying a synchronous codistribution peak in said synchronous codistribution plot that is associated with an aggregation of at least one of said proteins, peptides and peptoids; and using the synchronous co-distribution peaks to determine an overlap of distribution patterns of spectral intensities for the applied perturbation.

7. The step of using the synchronous co-distribution peaks includes the step of: １ and ν ２ 7. The method of claim 6, further comprising determining whether the synchronous co-distribution peaks corresponding to the two wavenumbers are within a certain range with respect to

8. applying two-dimensional correlation (2DCOS) analysis to generate synchronous and asynchronous correlation plots for at least one of said proteins, peptides and peptoids; identifying positive cross-peaks in said synchronous correlation plot that correlate with autopeaks associated with aggregation of at least one of said proteins, peptides and peptoids; and using the identified peak intensities of the spectral data to determine an amount of aggregation of at least one of the proteins, peptides and peptoids.

9. 9. The method of claim 8, further comprising the step of comparing the amount of aggregation of at least one of the proteins, peptides and peptoids with the order of occurrence of distributed spectral intensities for the applied perturbation.

10. The method of claim 1 further comprising determining the size and number of particulates to ascertain a population distribution of the particulates.

11. 10. The method of claim 1, further comprising analyzing the spectral data to at least one of verifying a signal to noise ratio, performing a baseline correction, determining water vapor content, and determining signal strength in a spectral region.

12. 10. The method of claim 1, further comprising generating covariance or dynamic spectral data based on perturbations of the sample.

13. 9. The method of claim 8, further comprising the step of correlating changes, including peak intensities, in the spectral data that are in phase with one another as obtained in the synchronous correlation plot.

14. The method of claim 1 further comprising determining a component that varies among the spectral data.

15. The method of claim 1 further comprising determining a maximum overall intensity change within the spectral data.

16. The method of claim 1 further comprising determining a minimum overall intensity change within the spectral data.

17. 10. The method of claim 1, further comprising the steps of determining a minimum number of underlying spectral contributions in a band, performing a curve-fitting analysis, and determining a secondary structural composition of the sample.

18. The method of claim 1 , further comprising increasing the resolution of the spectral data.

19. 9. The method of claim 8, further comprising the step of correlating variations, including peak intensities, in the spectral data that are out of phase with one another as obtained in the asynchronous correlation plot.

20. 2. The method of claim 1, further comprising determining the presence and / or extent of deamination of amino acid side chains in said at least one of said proteins, peptides and peptoids.

21. 10. The method of claim 1, further comprising determining the stability of a domain within said at least one of a protein, peptide and peptoid.

22. 1. A system for processing data representative of at least one characteristic of a protein, peptide, or peptoid, comprising: A data acquisition module comprising a Raman spectrometer, using said Raman spectrometer and without the use of exogenous probes or additives, successively acquiring a plurality of spectral images of at least one of said proteins, peptides and peptoids in solution, said successively acquired plurality of spectral images capturing induced changes in spectral intensity as a function of an applied perturbation; identifying and selecting a region of interest in at least one of the acquired spectral images that is related to the applied perturbation; selecting and analyzing spectral data in the region of interest of the plurality of consecutively acquired spectral images, the spectral data including data about side chains of amino acids of at least one of the proteins, peptides and peptoids in the solution, wherein analyzing the spectral data includes analyzing side chain modes of the at least one of the proteins, peptides and peptoids as an intrinsic probe; A correlation analysis module, applying a two-dimensional co-distribution (2DCDS) analysis to generate an asynchronous co-distribution plot of at least one of said proteins, peptides and peptoids; and the correlation analysis module configured to identify cross-peaks in the asynchronous co-distribution plot that are associated with aggregation of at least one of the proteins, peptides and peptoids.

23. 23. The system of claim 22, further comprising a visual model generator that generates one or more plots for display.

24. 23. The system of claim 22, further comprising a human interaction module comprising a human interface.

25. When executed by one or more computers, the one or more computers are using a Raman spectrometer and without the use of exogenous probes or additives, sequentially acquiring a plurality of spectral images of at least one of proteins, peptides and peptoids in solution, the plurality of sequentially acquired spectral images capturing induced changes in spectral intensity as a function of a controlled applied perturbation; identifying and selecting a region of interest in at least one of the acquired spectral images that is related to the applied perturbation; selecting and analyzing spectral data in the region of interest of the plurality of consecutively acquired spectral images, the spectral data including data about side chains of amino acids of at least one of the proteins, peptides and peptoids in the solution, the step of analyzing the spectral data including analyzing side chain modes of the at least one of the proteins, peptides and peptoids as an intrinsic probe; applying a two-dimensional co-distribution (2DCDS) analysis to generate an asynchronous co-distribution plot of at least one of said proteins, peptides and peptoids; identifying cross-peaks in said asynchronous codistribution plot that correlate with autopeaks associated with aggregation of at least one of said proteins, peptides and peptoids; and using the cross-peaks to determine an order of occurrence of distributed spectral intensities with respect to the applied perturbation.

26. and using the cross-peaks to determine an order of spectral intensities present in a distribution with respect to the applied perturbation.

27. 23. The system of claim 22, wherein the correlation analysis module further uses the cross-peaks to determine an order of spectral intensities present in a distribution with respect to the applied perturbation.

28. The proteins, peptides and peptoids are ２ 0) in solution.

Images